Market News Archives - Page 2 of 80 - Vista Partners LLC

Amylyx Ignites a New GLP-1 Investment Narrative as Clinical Data, Pharmacy Access and Diabetes Innovation Converge -( $AMLX $CVS $LLY $MODD $NVO )

by John F. Heerdink, Jr. 4 days ago 284Views 0Likes

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…

AI, Bond Yields and Big Bets: Why the Bull Case Is Getting More Selective -( $GOOG $NVDA )

by John F. Heerdink, Jr. 4 days ago 103Views 0Likes

This bullish market story examines how rising bond yields are reshaping—not ending—the investment opportunity set. It highlights **NVIDIA (NASDAQ: NVDA)** and its enormous AI data-center ambitions, **Alphabet (NASDAQ: GOOGL, GOOG)** and the growing strategic value of proprietary business data, and the emerging…

Stocks Retreat as Oil, Rates and Geopolitics Temper AI Optimism – Monday, August 17, 2026 -( $AXTI $EPRX $LPL $VIX Rise! )

by John F. Heerdink, Jr. 5 days ago 486Views 0Likes

U.S. stocks moved lower in afternoon trading and into the close on Monday as investors weighed rising geopolitical and energy-market risks against ongoing enthusiasm for artificial intelligence infrastructure. The selling was broad-based, with the Dow Jones Industrial Average, S&P 500, Nasdaq Composite,…

Heartflow’s AI-Cardiology Moment Arrives as Consumer Cyclicals Catch Their Breath -( $AMWL $HD $HTFL $LOW $TGT $WMT )

by John F. Heerdink, Jr. August 17, 2026 227Views 0Likes

Heartflow, Inc. (NASDAQ: HTFL) is delivering the kind of growth story investors usually hope to find before it becomes obvious: rapid revenue expansion, rising gross margins, stronger adoption of a second product line, and a materially higher full-year outlook. In a market…

The Energy Abundance Trade Is Getting Local -( $SOC $TE )

by John F. Heerdink, Jr. August 16, 2026 203Views 0Likes

The image above that depics the “largest oil producers” makes a persuasive point: the world is not short of hydrocarbons. The United States leads the list at 13.59 million barrels per day, ahead of Russia and Saudi Arabia, while Canada, Brazil, Guyana…

Weekly U.S. Market Summary: Records Meet a Consumer Reality Check – Friday, August 14, 2026 -( $EPRX $IGV $LPL $MODD $NFLX $NVDA $SMWB Rise! )

by John F. Heerdink, Jr. August 14, 2026 319Views 0Likes

U.S. equities finished a third consecutive winning week for the S&P 500 and Nasdaq Composite, supported by softer inflation signals, strong second-quarter earnings and renewed AI/software leadership. Friday’s weaker-than-expected July retail-sales report and a drop in consumer sentiment, however, introduced an important…

AI’s Memory Moment: Why SK Hynix Is Turning a Cyclical Chip Business Into Strategic Infrastructure -( $AMD $ASML $MU $MSFT $NVDA $SKHY )

by John F. Heerdink, Jr. August 14, 2026 272Views 0Likes

The artificial-intelligence boom is often told through the familiar names of the computing stack—NVIDIA Corp. (NASDAQ: NVDA), Advanced Micro Devices Inc. (NASDAQ: AMD), Microsoft Corp. (NASDAQ: MSFT), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN) and Meta Platforms Inc. (NASDAQ: META). But…

Sable Offshore: California’s Oil Restart Gets a Washington Tailwind -( $SOC $XOM )

by John F. Heerdink, Jr. August 13, 2026 234Views 0Likes

Sable Offshore Corp. (NYSE: SOC) is shaping up as one of the more unusual—and potentially compelling—U.S. energy turnaround stories: a concentrated, infrastructure-backed restart of offshore California oil production just as domestic supply security has returned to the policy conversation. The latest catalyst…

S&P 500 Extends Record Run While Producer Prices Forget to Inflate – Thursday, August 13, 2026 -( $AMWL $DOCS $EPRX $HPP $NVDA $SMCI $YSG Rise! )

by John F. Heerdink, Jr. August 13, 2026 235Views 0Likes

U.S. stocks finished broadly higher on Thursday, August 13, as investors welcomed a benign producer-inflation report and maintained confidence in the large-cap technology and artificial-intelligence growth narrative. All four major U.S. equity benchmarks—the S&P 500, Dow Jones Industrial Average, Nasdaq Composite, and…

Eupraxia Pharmaceuticals: A Clinical-Stage Biotech Where the Data Are Starting to Do the Talking -( $EPRX $SNY )

by John F. Heerdink, Jr. August 13, 2026 200Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) is developing a more persuasive story around EP-104GI: a long-acting, locally delivered treatment candidate for eosinophilic esophagitis (EoE) that has now shown durable improvement in both dysphagia and odynophagia. With an interim placebo-controlled Phase 2b…

Market News

Your Guide To Staying Informed In The Markets